Skip to content

Diltiazem effects on overactive bladder syndrome

A comparative study of tolterodine and diltiazem effects on OAB after prostatectomy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201105096424N1
Enrollment
80
Registered
2011-06-11
Start date
2011-05-31
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder syndrome. other specified disorders of bladder

Interventions

Intervention 1: Intervention group gives 60mg diltiazem oral tablet twice daily for one month. Intervention 2: Control group gives 2mg tolterodine oral tablet twice daily for one month.
Treatment - Drugs
Intervention group gives 60mg diltiazem oral tablet twice daily for one month.
Control group gives 2mg tolterodine oral tablet twice daily for one month.

Sponsors

Vice chancellor for research, kermanshah university of medical science
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients between 65 to 85 years old; with the history of prostatectomy in Emamreza Hospital; suffering OAB; agreement for enter to study. Exclusion criteria: Having systolic blood pressure under 90; bradicardia; congestive heart failure; bladder cancer; history of bladder radiation; interavesical BCG therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Patients symptoms of OAB. Timepoint: First of trial and one month later. Method of measurement: Questions of patients.

Secondary

MeasureTime frame
Side effects. Timepoint: First of trial and one month later. Method of measurement: Questions from patients.;Blood pressure. Timepoint: First of trial and one month later. Method of measurement: Blood pressure measurement mmhg.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkbar Heidaripoor

Kermanshah university of medical science

dr.ak.heidaripoor@kums.ac.ir; omid8772@yahoo.com+98 83 1427 6309

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026